Lupin buys SA firm, to expand product portfolio
Lupin Limited (Lupin), the Rs 6,000-crore Mumbai-based pharmaceutical company is planning to expand its drug portfolio in India.Updated: Sep 18, 2008, 21:47 IST
Lupin Limited (Lupin), the Rs 6,000-crore Mumbai-based pharmaceutical company is planning to expand its drug portfolio in India. The company, which announced its fifth acquisition abroad today in form of Pharma Dynamics (PD) in South Africa, plans to enter the eye and skin care segments in its home country.
“We are entering the ophthalmology segment and are closely watching the dermatology market. We intend to launch products in these two fields shortly,” DB Gupta, chairman, Lupin told Hindustan Times.
The skincare or dermatology market was Rs 2100 crore in 2007 and is growing at close to 20 per cent, according to analysts, while the ophthalmology, or eye care market, is pegged at between 160 to 200 crore, depending on whether the over-the-counter or non-prescription drugs are counted or not.The company is also planning to start separate divisions to cater to these rapidly growing markets, said sources in the company.